Table 2 Background of patients with pathological high-risk (pT3-4, ypT2-4, or pN+).
From: Trends in the use and efficacy of adjuvant immunotherapy in muscle-invasive urothelial carcinoma
No adjuvant | Adjuvant chemotherapy | Adjuvant ICIs | |
|---|---|---|---|
Number of patients, n | 764 | 274 | 63 |
Age, years (IQR) | 72 (66, 78) | 69 (62, 75) | 73 (67, 76) |
Male, n | 537 (70.3%) | 206 (75.2%) | 44 (69.8%) |
ECOG PS > 1, n | 29 (3.8%) | 6 (2.2%) | 0 (0%) |
eGFR, mL/min/1,73 m2 (IQR) | 57.7 (44.9, 71.5) | 58.8 (48.1, 73.5) | 55.0 (38.8, 63.5) |
UTUC, n | 282 (36.9%) | 148 (54.0%) | 22 (34.9%) |
Neoadjuvant chemotherapy, n | 434 (17.5%) | 36 (13.1%) | 61 (96.8%) |
pT > 2 or ypT > = 2, n | 732 (95.8%) | 262 (95.6%) | 61 (96.8%) |
pN+, n | 179 (23.4%) | 100 (36.5%) | 20 (31.7%) |
Variant histology, n | 134 (17.5%) | 36 (13.1%) | 11 (17.5%) |
Type of adjuvant immunotherapy | |||
nivolumab, n | 0 (0%) | 0 (0%) | 60 (0%) |
Atezolizumab, n | 0 (0%) | 0 (0%) | 3 (0%) |
Median follow up, months | 30.8 (11.4, 75.1) | 34.3 (17.0, 71.5) | 14.8 (8.1, 21.8) |
Nonurothelial tumor recurrence, n | 497 (65.1%) | 174 (63.5%) | 18 (28.6%) |
Deceased, n | 334 (43.7%) | 110 (40.1%) | 4 (6.35) |
